Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Oncology Année : 2018

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma

1 Service de dermatologie [Rouen]
2 PANTHER - Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices
3 CHU Rouen
4 CHU Bordeaux
5 Hôpital Saint-André
6 CRCINA-ÉQUIPE 2 - Clinical and Translational Research in Skin Cancer
7 CHU Nantes - Centre Hospitalier Universitaire de Nantes
8 CIC Nantes - Centre d’Investigation Clinique de Nantes
9 Service de Dermatologie [CHU Cochin]
10 UPD5 - Université Paris Descartes - Paris 5
11 Hôpital Claude Huriez [Lille]
12 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
13 CRLCC - CRLCC Eugène Marquis
14 TIMONE - Hôpital de la Timone [CHU - APHM]
15 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
16 Service de dermatologie (CHRU de Tours)
17 Université Francois Rabelais [Tours]
18 CEF2P / CARCINO - Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181)
19 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
20 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
21 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
22 Centre Hospitalier Le Mans (CH Le Mans)
23 Service de Dermatologie (CHU de Dijon)
24 CHU Nice - Centre Hospitalier Universitaire de Nice
25 C3M - Centre méditerranéen de médecine moléculaire
26 Service de dermatologie [CHU d'Amiens-Picardie]
27 Hôpital universitaire Robert Debré [Reims]
28 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
29 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
30 UCBL - Université Claude Bernard Lyon 1
31 Hôpital Avicenne [AP-HP]
32 UP13 - Université Paris 13
33 CHU Angers - Centre Hospitalier Universitaire d'Angers
34 UNAM - PRES Université Nantes Angers Le Mans
35 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
36 UNISTRA - Université de Strasbourg
37 CHU de Poitiers - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
38 GHH - Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS)
39 CHU Caen
40 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
André Gillibert
Thierry Lesimple
Caroline Gaudy-Marqueste
  • Fonction : Auteur
  • PersonId : 967066
Andreea Stefan
  • Fonction : Auteur

Résumé

Background: The objective was to assess the response rate and survival of patients with metastatic mucosal melanoma (MM) and uveal melanoma (UM) treated with anti-CTLA-4 or anti-PD-1 monoclonal antibodies (mAbs). Methods: A multicenter retrospective study was performed in 25 dermatology departments in France. All patients with stage III-C to IV MM or UM who were treated with anti-CTLA-4 or anti-PD-1 mAbs between 2008 and 2016 were included and compared after adjustment for main prognostic factors with a second cohort of patients treated with chemotherapy. Tumor response was evaluated according to RECIST v. 1.1 criteria at Week 12. Results: Four-hundred-and-thirty-nine patients were included, 229 MM (151 immunotherapy, 78 chemotherapy) and 210 UM (100 immunotherapy, 110 chemotherapy). Response rates of MM patients treated with immunotherapy were 18/151 (11.9%; 95% CI:7.2%-18.2%), versus 11/78 (14.1%, 95% CI:7.3%-23.8%) in patients treated with chemotherapy (p=0.87). No tumor response was observed in UM patients treated with immunotherapy, versus 4/110 responses (3.6%, 95% CI:1.0-9.0%) in patients treated with chemotherapy (p=0.15). The adjusted overall survival (OS) of MM patients treated with immunotherapy was longer than that of patients treated with chemotherapy HR=0.62 (95% CI: 0.43-0.91), p=0.014, with an unadjusted median OS of 15.97 months [interquartile range (IQR)=6.89-27.11] and 8.82 months [IQR=5.02-14.92], respectively. The adjusted OS of UM patients treated with immunotherapy was not significantly different from that of patients treated with chemotherapy (HR=0.98, 95% CI: 0.66-1.44) p=0.92, with an unadjusted median OS of 13.38 months [IQR=6.03-29.57] and 11.02 months [IQR=6.13-23.93], respectively. Conclusion: Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor.
Immunotherapy significantly improves OS for MM. The prognosis of metastatic UM remains poor.

Dates et versions

hal-02377599 , version 1 (23-11-2019)

Identifiants

Citer

Claire Mignard, Aurélie Deschamps Huvier, André Gillibert, Anne Bénédicte Duval Modeste, Caroline Dutriaux, et al.. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. Journal of Oncology, 2018, 2018, pp.1-9. ⟨10.1155/2018/1908065⟩. ⟨hal-02377599⟩
119 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More